54231-41-3

Usage

Uses

Used in Research Applications:
(3-Bromo-pyridin-2-yl)-hydrazine is used as a research chemical for the synthesis and study of various organic compounds and their derivatives. Its unique structure allows for the exploration of its potential interactions and reactions with other molecules, contributing to the advancement of chemical research.
Used in Industrial Applications:
In the industrial sector, (3-Bromo-pyridin-2-yl)-hydrazine is employed as an intermediate in the production of various chemical products. Its versatility in chemical reactions makes it a valuable component in the synthesis of a wide range of compounds, which can be further utilized in different industries.
Used in Pharmaceutical Development:
(3-Bromo-pyridin-2-yl)-hydrazine is used as a building block in the development of new pharmaceutical compounds. Its structural properties enable the creation of potential drug candidates, which can be tested for their therapeutic effects and safety profiles in the treatment of various diseases and medical conditions.
Used in Material Science:
In the field of material science, (3-Bromo-pyridin-2-yl)-hydrazine is used as a component in the development of new materials with specific properties. Its incorporation into the molecular structure of these materials can lead to the creation of materials with unique characteristics, such as improved stability, reactivity, or selectivity, which can be applied in various applications.

Upstream product

• 52200-48-3 3-bromo-2-chloropyridine 
• 13534-89-9 2,3-dibromopyridine 

Downstream Products

• 1140898-99-2 N'-(3-bromopyridin-2-yl)-4-(3-(4-fluorophenyl)-1,2,4-oxadiazol-5-yl)bicyclo[2.2.2]octane-1-carbohydrazide 
• 1140898-81-2 N'-(3-bromopyridin-2-yl)-1-(4-chlorophenyl)cyclopropane-carbohydrazide 
• 1190392-72-3 N'-(3-bromopyridin-2-yl)acetohydrazide 
• 54230-91-0 8-bromo-3-phenyl-[1,2,4]triazolo[4,3-a]pyridine 
• 1140897-32-0 2-(3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)propan-2-ol 
• 54230-90-9 8-bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine 
• 1610951-86-4 8-([1,1'-biphenyl]-2-yloxy)-3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridine 
• 1610951-81-9 3-(1-(4-chlorophenyl)cyclopropyl)-8-(2-(methylsulfonyl)phenoxy)-[1,2,4]triazolo[4,3-a]pyridine 
• 1610951-77-3 2-((3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)oxy)phenol 
• 1610951-73-9 3-(1-(4-chlorophenyl)cyclopropyl)-8-(2-(trifluoromethoxy)phenoxy)-[1,2,4]triazolo[4,3-a]pyridine 
• 1610951-70-6 4-(2-((3-(1-(4-chlorophenyl)cyclopropyl)-[1,2,4]triazolo[4,3-a]pyridin-8-yl)oxy)phenyl)morpholine 
• 1310692-29-5 3-(1-(4-chlorophenyl)cyclopropyl)-8-(2-fluorophenoxy)-[1,2,4]triazolo[4,3-a]pyridine 

Relevant academic research and scientific papers

BENZYL-, (PYRIDIN-3-YL)METHYL- OR (PYRIDIN-4-YL)METHYL-SUBSTITUTED OXADIAZOLOPYRIDINE DERIVATIVES AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS

The present invention relates to compounds of general formula (I), wherein the groups R1 and R2 are defined as in claim 1, which have valuable pharmacological properties, in particular bind to ghrelin O-acyl transferase (GOAT) and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular obesity.

Discovery of Clinical Candidate BMS-823778 as an Inhibitor of Human 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD-1)

BMS-823778 (2), a 1,2,4-triazolopyridinyl-methanol derived analog, was identified as a potent and selective inhibitor of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1) enzyme (IC50 = 2.3 nM) with >10,000-fold selectivity over 11β-HSD-2. Compound 2 exhibits robust acute pharmacodynamic effects in cynomolgus monkeys (ED50 = 0.6 mg/kg) and in diet-induced obese (DIO) mice (ED50 = 34 mg/kg). Compound 2 also showed excellent inhibition in an ex vivo adipose DIO mouse model (ED50 = 5.2 mg/kg). Oral bioavailability ranges from 44% to 100% in preclinical species. Its favorable development properties, pharmacokinetics, high adipose-to-plasma concentration ratio, and preclinical pharmacology profile have prompted the evaluation of 2 for the treatment of type 2 diabetes and metabolic syndrome in phase 2 clinical trials.

The synthesis and analysis of [phenyl-14C(U)]BMS-770767 and [13C6]BMS-770767 for use in discovery biotransformation, human ADME and bioanalytical studies

Type 2 diabetes is a significant worldwide health problem. To support the development of BMS-770767 as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) for type 2 diabetes was required the synthesis of carbon-14-labelled material for use in metabolic profiling and for the human adsorption, distribution, metabolism and excretion (ADME) study. Initially, [phenyl-14C(U)]BMS-770767 was synthesized in two steps from a late-stage intermediate and [14C(U)]2-chlorophenol to give the desired final product in 18% yield. Later, the synthesis was completed for the human ADME clinical study using a combination of the discovery and process chemistry routes under cGMP to prepare [phenyl-14C(U)]BMS-770767. The radiochemical purity of the synthesized [phenyl-14C(U)]BMS-770767 after dilution with unlabelled clinical grade BMS-770767 was 99.1% having a specific activity of 1.61 μCi/mg. In addition, to support the quantification of BMS-770767 in LC/MS analyses, [13C6]BMT-770767 was prepared in two steps from a late-stage intermediate and [13C6]2-chlorophenol.

Optimization of 1,2,4-triazolopyridines as inhibitors of human 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD-1)

Small alkyl groups and spirocyclic-aromatic rings directly attached to the left side and right side of the 1,2,4-triazolopyridines (TZP), respectively, were found to be potent and selective inhibitors of human 11β- hydroxysteroid dehydrogenase-type 1 (11β-HSD-1) enzyme. 3-(1-(4-Chlorophenyl)cyclopropyl)-8-cyclopropyl-[1,2,4]triazolo[4,3-a]pyridine (9f) was identified as a potent inhibitor of the 11β-HSD-1 enzyme with reduced Pregnane-X receptor (PXR) transactivation activity. The binding orientation of this TZP series was revealed by X-ray crystallography structure studies.

TRIAZOLOPYRIDINONE PDE10 INHIBITORS

The present invention is directed to triazolopyridinone compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

IMIDAZOLE DERIVATIVES

Described herein are compounds of formula (I) :The compounds of formula I act as DGAT1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for hyperlipidemia, diabetes mellitus and obesity.

TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS

Novel compounds are provided which are 11 -beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxyster

HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS

The present invention provides compounds of Formula I, pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.